Advertisement
Advertisement
ADMA
ADMA Biologics, Inc.
12.73
USDSponsored
-0.48
-3.63%
Nov 06, 15:59 UTC -5
Closed
After-Market
12.89
+0.16
+1.26%
ADMA Biologics, Inc. (ADMA) Earnings
ADMA Earnings Reports
Positive Surprise Ratio
ADMA beat 20 of 44 last estimates.
45%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
ADMA Biologics, Inc. earnings per share and revenue
On Nov 04, 2026, ADMA reported earnings of 0.22 USD per share (EPS) for Q3 26, beating the estimate of 0.19 USD, resulting in a 10.61% surprise. Revenue reached 141.10 million, compared to an expected 140.95 million, with a 0.10% difference. The market reacted with a +26.05% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
What were ADMA Biologics, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, ADMA Biologics, Inc. reported EPS of $0.22, beating estimates by 10.61%, and revenue of $141.10M, 0.1% above expectations.
How did the market react to ADMA Biologics, Inc.'s Q3 2026 earnings?
The stock price moved up 26.05%, changed from $10.48 before the earnings release to $13.21 the day after.
When is ADMA Biologics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for ADMA Biologics, Inc.'s next earnings report?
Based on --
analysts, ADMA Biologics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.